openPR Logo
Press release

How Sanofi is dominating the Global Fabry Disease Treatment Market

05-02-2022 06:05 PM CET | Health & Medicine

Press release from: Flair Intelligence

How Sanofi is dominating the Global Fabry Disease Treatment

The purpose of the strategic research study titled "Fabry Disease Treatment Market - GLOBAL Industry Perspective Comprehensive Analysis and Forecast 2020 - 2028" is to offer industry investors, company executives, and industry participants with in-depth analysis to enable them make informed strategic decisions related to the opportunities in the industry.

4D Molecular's lead product candidate for treatment of Fabry and other lysosomal storage disorders is 4D-310, which uses a proprietary vector design for efficient delivery to relevant tissues with minimal toxicity and resistance to pre-existing antibodies. The Company has completed a pre-IND discussion with the FDA and will initiate a phase 1/2 clinical trial for the H2,2020. The discussion was on the basis of an IND-enabling pharmacology and Good Laboratory Practices (GLP) toxicology and biodistribution study that was initiated in 2019.

The Company uses its proprietary mRNA platform to discover and create novel solutions across indications such as prophylactic vaccine development, personalized cancer vaccine, intra-tumoral immune-oncology and localized regenerative medicine to name a few. Moderna has developed a unique mRNA sequence that codes for a protein, and encompasses knowledge of mRNA biology, chemistry, formulation & delivery, bioinformatics and protein engineering to address unmet needs in critical areas.
The Platform offers great flexibility and wide applicability; by changing the sequence of the genetic code it can combine different mRNA sequences for different proteins in a single mRNA medicine. It has a drug design studio, which can develop mRNA within a very short period of time, using a proprietary Sequence Designer module, bioinformatics algorithms and its modular synthesis robotics, making it a pioneering Digital Biotech Company.

The Company is developing a treatment for Fabry disease as part of its systemic secreted therapeutics modality, besides developing therapeutics for methylmalonic acidemia (MMA), propionic acidemia (PA), glycogen storage disorder Type 1a (GSD1a) and through its systemic intracellular therapeutics modality. mRNA-3630 is currently undergoing pre-clinical evaluation and the Company intends to file for an IND soon.

Scientists and researchers are utilizing big efforts while searching for new treatment options for Fabry disease treatment. As per estimation, nearly billions of dollars are invested in developing a treatment through gene therapy. Unfortunately, a lot of that effectively goes down the drain as money spent on the nine out of ten therapies that fail somewhere between phase I trials and regulatory approvals. Gene therapy for Fabry disease is designed to introduce a healthy copy of the GLA gene inside cells to restore normal levels of the alpha-galactosidase-A enzyme. This approach is still in the experimental stages.
Gene Therapy for Fabry Disease-
• FLT190- It is an experimental gene therapy which is being developed by Freeline. This study is currently in Phase 1/2 clinical trial (NCT04040049) and is currently recruiting up to 15 patients of age 18 and older, at sites in the U.K., Norway, and Italy.
• ST-920- This experimental gene therapy is being developed by Sangamo Therapeutics. Currently in Phase 1/2 clinical trial (NCT04046224), this study is recruiting about 30 adults with across 6 sites in the U.S. to test the safety and efficacy of ascending doses of a single infusion of this therapy.

For further report overview visit @ https://flairintelligence.com/know-how-sanofi-is-dominating-the-global-fabry-disease-treatment-market-forecast-and-opportunities/

Office A & B, Kakade Terrace
Warje, Pune 411058
Mail: info@flairintelligence.com

Flair Intelligence is market research and consulting firm, with a vast expertise in technology and consumer goods reports. Our colossal repository of research reports, would present you with an in depth details about the market ranging from evolving trends, competitive analysis and bench marking, lucrative investment pockets,which will help your business drive profitable growth.

Our research methodology is designed to provide all your research needs, backed by effective quantitative and qualitative analysis (Surveys, hypothesis formation and estimation ).

Our Major Services

Custom Research
Industry Monitoring Services
Syndicate Research

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release How Sanofi is dominating the Global Fabry Disease Treatment Market here

News-ID: 2615235 • Views: 496

More Releases from Flair Intelligence

Know more about the consumer trends in European Flip Flops Market
The government enforced lockdown rules all around the world, are forcing individuals to stay at home. The demand for lightweight sole materials in footwear has plunged as there have been no physical activities, lowering the demand for sports shoes in various games and physical activities. Due to the factory lockdown and manpower shortage, production in the footwear industry has come to a halt. The virus is wreaking havoc on the economy,
How Colombia is gaining a colossal traction within the mobile gaming market
The Colombia Instant Pay Game market is projected to reach USD 405 million by 2026, from USD 227 million in 2020 and is anticipated to register a CAGR of 10.1% between 2021 and 2026. Despite geopolitical tensions, the growing smartphone penetration and increasing gaming options are also increasing the mobile gaming penetration in many parts of the world. For instance, according to White Designers Game Studios, in Iran, with a population
How TE Connectivity, Amphenol Sine Systems and Molex is dominating the Global In …
The purpose of the strategic research study titled "Industrial Connectors Market - Global Industry Perspective Comprehensive Analysis and Forecast 2021 - 2028" is to offer industry investors, company executives, and industry participants with in-depth analysis to enable them make informed strategic decisions related to the opportunities in the industry. Industrial and multiphase plugs and sockets provide a connection to the electrical mains rated at higher voltages and currents than household plugs
Global Dried Beans Market: Know All Insights and Competitive Analysis About the …
The global Dry Beans market is projected to reach USD 40,822 million by 2026, from USD 31,130 million in 2020 and is anticipated to register a CAGR of 4.8% between 2021 and 2026. Due to the Covid-19 outbreak and the imposition of lockdown restrictions, there was a surge in demand for dry beans because of their long shelf-life. The global pandemic has made people health-conscious, and has made them to shift towards consuming organic,

All 5 Releases


More Releases for Fabry

Fabry Disease Market Expected to Rise Steadily throughout 2026
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of
Fabry Disease - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H2 201 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H2 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called
Fabry Disease Market show exponential growth by 2023
Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in a severe form
Fabry Disease Market | Analysis & Key Trends 2023
Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called
Fabry Disease Market Intelligence Report Offers Growth Prospects
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of